Savaysa, Lixiana(edoxaban)
Lixiana, Roteas, Savaysa (edoxaban) is a small molecule pharmaceutical. Edoxaban was first approved as Savaysa on 2015-01-08. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat stroke and venous thromboembolism. The pharmaceutical is active against coagulation factor X.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Savaysa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Edoxaban tosylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SAVAYSA | Daiichi Pharmaceutical | N-206316 RX | 2015-01-08 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| savaysa | New Drug Application | 2024-02-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| venous thrombosis | HP_0004936 | D020246 | I82.40 |
| pulmonary embolism | HP_0002204 | D011655 | I26 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
EDOXABAN TOSYLATE, SAVAYSA, DAIICHI SANKYO INC | |||
| 2026-10-18 | M-14 | ||
HCPCS
No data
Clinical
Clinical Trials
188 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 8 | 12 | 18 | 47 | 85 |
| Thromboembolism | D013923 | HP_0001907 | — | 1 | 3 | 8 | 2 | 16 | 30 |
| Thrombosis | D013927 | — | — | 1 | 6 | 4 | 7 | 12 | 30 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 1 | 2 | 7 | 2 | 15 | 27 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 4 | 6 | 7 | 11 | 27 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 2 | 2 | 7 | 4 | 5 | 20 |
| Ischemic stroke | D000083242 | — | — | — | 2 | 3 | 3 | 10 | 17 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 1 | 3 | 4 | 2 | 6 | 16 |
| Embolism | D004617 | — | — | 1 | 2 | 4 | 2 | 4 | 13 |
| Neoplasms | D009369 | — | C80 | — | — | 2 | 2 | 4 | 8 |
Show 34 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | 4 | 5 |
| Covid-19 | D000086382 | — | — | — | — | 2 | — | 1 | 3 |
| Traumatic intracranial hemorrhage | D020198 | — | — | — | — | 3 | — | — | 3 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | 2 | — | 1 | 3 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | 1 | — | 1 | 2 |
| Cerebral hemorrhage | D002543 | — | — | — | 1 | 1 | — | — | 2 |
| Subdural hematoma | D006408 | HP_0100309 | — | — | — | 1 | — | 1 | 2 |
| Hematoma | D006406 | EFO_0010680 | — | — | — | 1 | — | 1 | 2 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | 1 | — | — | 1 |
| Hypertensive intracranial hemorrhage | D020299 | — | — | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | 3 | — | — | 1 | 6 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | 1 | — | — | 1 | 2 |
| Blood coagulation | D001777 | GO_0007596 | — | — | 1 | — | — | 1 | 2 |
| Replacement arthroplasty hip | D019644 | — | — | — | 2 | — | — | — | 2 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | 1 | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | — | 1 |
| Embolism and thrombosis | D016769 | — | — | — | 1 | — | — | — | 1 |
| Replacement arthroplasty knee | D019645 | — | — | — | 1 | — | — | — | 1 |
| Pathologic constriction | D003251 | — | — | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coagulation protein disorders | D020147 | — | — | 2 | — | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Bariatric surgery | D050110 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | — | — | 4 | 4 |
| Postphlebitic syndrome | D011186 | — | I87.0 | — | — | — | — | 3 | 3 |
| Postthrombotic syndrome | D054070 | EFO_0007452 | I87.0 | — | — | — | — | 3 | 3 |
| Frailty | D000073496 | — | R53.1 | — | — | — | — | 3 | 3 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | — | — | — | 2 | 2 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 2 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 2 | 2 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Oral surgery | D013515 | — | — | — | — | — | — | 1 | 1 |
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Edoxaban |
| INN | edoxaban |
| Description | Edoxaban is a monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism. It has a role as an anticoagulant, an EC 3.4.21.6 (coagulation factor Xa) inhibitor and a platelet aggregation inhibitor. It is a monocarboxylic acid amide, a chloropyridine, a thiazolopyridine and a tertiary amino compound. It is a conjugate base of an edoxaban(1+). |
| Classification | Small molecule |
| Drug class | antithrombotics, blood coagulation factor XA inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1 |
Identifiers
| PDB | — |
| CAS-ID | 480449-70-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1269025 |
| ChEBI ID | 85973 |
| PubChem CID | 10280735 |
| DrugBank | DB09075 |
| UNII ID | NDU3J18APO (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,899 documents
View more details
Safety
Black-box Warning
Black-box warning for: Savaysa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,905 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use